Jiangsu Lianhuan Pharmaceutical (600513.SH) subsidiary Aisizolun tablets passed consistency evaluation.
Lianhuan Pharmaceutical (600513.SH) announced that its controlling subsidiary, Xinxiang Changle Pharmaceutical Co., Ltd. (referred to as "Changle Pharmaceutical"), recently received the approval notice issued by the National Medical Products Administration for the supplementary application for approval of the Alprazolam Tablets, approving Changle Pharmaceutical's original product to pass the generic drug quality and efficacy consistency evaluation.
Jiangsu Lianhuan Pharmaceutical (600513.SH) announced that its controlling subsidiary, Xinxiang Changle Pharmaceutical Co., Ltd. ("Changle Pharmaceutical"), recently received the approval notice from the National Medical Products Administration for the supplementary application for the production of Alprazolam Tablets. This approval allows Changle Pharmaceutical's product to pass the generic drug quality and efficacy consistency assessment.
Alprazolam Tablets are mainly used for anti-anxiety and insomnia, as well as for tension, fear, anti-epileptic, and anti-convulsive purposes. This drug is a commonly used benzodiazepine sedative-hypnotic medication in clinical practice.
Related Articles
Yum China (09987) spent approximately 10.4 million US dollars on December 3 to repurchase 218,200 shares.
SINO BIOPHARM(01177): TQF3250 "Orally predominant GLP-1 receptor agonist" clinical trial application approved by NMPA and FDA.
On December 4, Tencent (00700) spent approximately HK6.36 billion to buy back 1.044 million shares.
Yum China (09987) spent approximately 10.4 million US dollars on December 3 to repurchase 218,200 shares.
SINO BIOPHARM(01177): TQF3250 "Orally predominant GLP-1 receptor agonist" clinical trial application approved by NMPA and FDA.
On December 4, Tencent (00700) spent approximately HK6.36 billion to buy back 1.044 million shares.
